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Abstract
The use of dabigatran, a non-vitamin K antagonist (VKA) oral anticoagulant, is still increasing. Dabigatran has a good 
efficacy and safety ratio, as well as a more predictable anticoagulation effect compared with VKA. On the other hand, 
there is acenocoumarol/warfarin, a VKA which was evaluated in numerous clinical trials and is a drug of choice in 
a valve-related atrial fibrillation (AF).
Based on the real clinical cases, we attempted to summarize current recommendations on how to manage periproce-
dural complications on oral anticoagulant treatment.
In the first case we presented a patient on dabigatran, undergoing pulmonary vein isolation (PVI) of AF, who developed 
a right groin hematoma after the procedure and hence required several blood transfusions. In the second case we 
showed a patient on acenocoumarol, with high bleeding risk, who developed a pocket hematoma after an implantable 
cardioverter-defibrillator (ICD) implantation. We also reported a patient on dabigatran, who developed a femoral artery 
pseudoaneurysm (FAP) following PVI of AF.
Periprocedural oral anticoagulation depends on the anticoagulant type and requires individual assessment of the 
patient’s thromboembolic and bleeding risk factors. Our case reports showed that in case of a bleeding, dabigatran 
may be quickly stopped and then restarted recently after reaching hemostasis, in contrast to acenocoumarol. They also 
confirm a possibility of successful pseudoaneurysm closure without dabigatran suspension.
Key words: acenocoumarol, dabigatran, hematoma, periprocedural complications, pulmonary vein isolation,  
implantable cardioverter-defibrillator, pseudoaneurysm
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Introduction
Oral anticoagulant therapy is commonly used in an everyday 
practice. However, clinicians have to deal with a thrombotic 
and bleeding risk, which frequently is problematic, espe-
cially in patients requiring invasive treatment. Currently no 
evidence-based guidelines are available for periprocedural 
complications in anticoagulated patients. Pulmonary vein 
isolation (PVI) of atrial fibrillation (AF) and implantation of 
cardiac rhythm devices are associated with a 1–2% risk 
of serious bleedings (tamponade, hemothorax) and 5% of 
minor bleedings (groin bleedings, hematomas). However, 
incidence of those complications is decreasing in recent 
trials [1].
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Dabigatran, as a non-vitamin K antagonist (VKA) oral 
anticoagulant (NOAC), is a treatment of choice for thrombo-
-embolic prevention in patients with a non-valvular AF [1]. 
The aim of this paper was to summarize the principles of 
management of periprocedural complications, during diffe-
rent oral anticoagulant treatment. We presented two cases 
of patients using dabigatran (treated with PVI) and one case 
of a patient using acenocoumarol after ICD implantation.
Case details
Case 1
A 64-year-old female with persistent AF was admitted for 
PVI. Medical history included arterial hypertension and 
obesity, with normal renal and liver function. The patient 
was assessed on 2 points in CHA2DS2VASc score and on 
1 point in HAS-BLED score. AF, lasting from about 3 ye-
ars, was symptomatic (EHRA III, European Heart Rhythm 
Association). Before admission, the patient was receiving 
perindopril, bisoprolol, spironolactone, propafenone and 
dabigatran (150 mg bid). On presentation, her vitals were: 
blood pressure (BP) 140/90 mm Hg, pulse was irregular — 
around 90 bpm. Clotting times were normal. On the second 
day of the hospitalization the patient underwent a PVI 
and was admitted in a good general condition to intensive 
cardiac care unit for monitoring. After eight hours of the 
pressure bandage observation, hematoma appeared in the 
right groin (Figure 1A). Cardiovascular examination showed 
signs of a hemorrhagic shock: tachycardia — 100 bpm, 
BP 100/60 mm Hg. Laboratory findings were: red blood 
cells (RBC) — 2.82 × 106/μl (baseline: 4.22 × 106/μl) and 
hemoglobin — 8.3 g/dl (baseline: 12.7 g/dl). At that time 
the patient received aggressive IV fluid replacement. In the 
following few hours, further decrease of blood parameters 
was observed: RBC — 2.34 × 106/μl, hemoglobin — 7.2 g/dl 
and hematocrit — 21.1%. Group and cross-match was taken. 
The patient was transfused one unit of packed RBC (PRBC), 
with poor outcome and in the next day another two units, 
reaching RBC — 3.2 × 106/μl and hemoglobin 10.0 g/dl. 
Her BP improved to 132/69 mm Hg and pulse to 85 bpm. 
Large intramuscular hematoma with three compartments 
(the largest was 64 × 20 × 54 mm) (Figure 1B) was reve-
aled in USG of the right groin. It was concluded that the 
bleeding was likely an adverse effect of a daily dabigatran 
therapy. Dabigatran was continued through the hospitaliza-
tion except the ablation day. During further hospitalization 
a control USG study confirmed hematoma absorption and 
the patient was discharged in a good general condition.
Case 2
A 79-year-old man with dilated cardiomyopathy and seve-
re heart failure was readmitted 14 days after implantation 
(9 days after discharge) of a single-chamber cardioverter-
-defibrillator (ICD) with a pocket hematoma. Relevant 
medical history included: chronic acenocoumarol treat-
ment due to persistent AF, chronic kidney disease stage 
G3b, post-thrombotic syndrome and percutaneous mitral 
valve repair with MitraClip. Before admission, the patient 
received furosemide, ramipril, carvedilol, eplerenone, al-
lopurinol and acenocoumarol (4 mg OD). On presentation, 
large hematoma with a superficial bruise on the anterior 
chest was seen (Figure 2A). The patient did not suffer 
from chest pain or shortness of breath. His vitals were: 
BP 93/62 mm Hg and irregular pulse — around 75 bpm. 
Laboratory findings were: hemoglobin – 10.7 g/dl (last 
known: 11.24 g/dl), platelets — 253 × 103/μl (normal 
range 150–400 × 103/μl), creatinine — 1.52 mg/dl, INR — 
2.21, prolonged APTT — 52.9 s. USG of the chest revealed 
a large pocket hematoma with dimensions 42 × 48 × 8 mm 
(Figure 2B). Firstly, a sterile compression therapy was 
applied. It was concluded that hematoma was likely an 
adverse effect of acenocoumarol, which was wherefore 
suspended and replaced by enoxaparine (80 mg od) after 
one day cessation of the anticoagulation therapy. On con-
secutive day the hematoma was evacuated. After 2 weeks 
of the further hospitalization the hematoma absorption 
was observed and acenocoumarol was then gradually re-
started with a low dose (2 mg). The patient was discharged 
in a good general condition, with the recommendations of 
INR level check every 2–3 weeks.
Figure 1A. Anteroposterior view of a large groin hematoma after pulmonary vein isolation in a patient with atrial fibrillation; B. Ultrasound 
sonography shows dimensions of the intramuscular hematoma
A B
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(Figure 3B). Consulting vascular surgeon applied a percu-
taneous injection of thrombin into the pseudoaneurysm 
cavity, without dabigatran suspension. Clotting of the pseu-
doaneurysm was obtained. The patient was discharged 
3 days after ablation without any complications.
Discussion
High dose (150 mg bid) of dabigatran has an improved effi-
cacy and comparable safety ratio, does not require routine 
monitoring because of a predictable effect, fewer food and 
drug interactions, compared with VKA [1], as presented in 
Table 1. Dabigatran and warfarin (which was used in most 
of the clinical trials comparing VKA drugs, but it has similar 
characteristics to acenocoumarol) have similar numbers of 
thrombo-embolic and bleeding events in patients undergo-
ing PVI of AF and implantation of cardiac rhythm devices 
[2, 3]. Consensus statement recommended uninterrupted 
Case 3
A 66-year-old man, with a paroxysmal AF and atrial flutter was 
admitted to the hospital for a transcutaneous radiofrequency 
ablation of the arrhythmia. The symptoms were assessed 
as EHRA III. Medical history included stable coronary artery 
disease, arterial hypertension, diabetes mellitus type 2, 
hyperthyroidism, and hyperlipidemia. Renal and liver fun-
ction were normal. The patient was assessed on 3 points in 
CHA2DS2VASc score and on 2 points in HAS-BLED score. The 
patient before admission was receiving valsartan, metopro-
lol, metformin, gliclazide, dabigatran (150 mg bid, it was 
continued through the hospitalization except the ablation 
day). On presentation, his vitals were: BP 135/70 mm Hg, 
pulse was irregular — around 72 bpm. Next day after ab-
lation, after removal of the pressure dressing, skin bruise 
was presented (Figure 3A). Furthermore murmur and severe 
pain in the right groin was found. Control US study revealed 
a femoral artery pseudoaneuysm (FAP) (38 × 30 × 15 mm) 
Figure 2A. Anteroposterior view of a chest bruise in a patient who underwent a device implantation; B. Ultrasound sonography shows 
dimensions of the pocket hematoma
A B
Figure 3A. Anteroposterior view of a skin bruise of the right groin in a patient who underwent pulmonary vein isolation; B, C. Ultrasound 
sonography view of the pseudoaneurysm
A C
B
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VKA treatment (with target INR 2.0–2.5) performing PVI 
because of lower rate of thrombo-embolic and bleeding 
events (compared with interrupted treatment) [4]. Recently 
dabigatran demonstrated similar safety to warfarin, giving 
the opportunity for continuous proceeding with OAC [4], 
but still it is recommended to stop dabigatran ≥ 24 h prior 
to a procedure.
In the 1st case, there was presented intramuscular 
bleeding after right femoral vein puncture for PVI. A bleeding 
risk of our patient was assessed as low and according to 
the recommendations, dabigatran was stopped 24 h be-
fore the PVI (Table 2) [1]. It is suggested that the activated 
partial thromboplastin time (APTT) independently predict 
periprocedural complications in the dabigatran group [5]; 
however, clotting times of our patient before procedure 
were normal and after were unknown. During the ablation, 
the active clotting time (ACT) test is used because of high 
heparin doses and that APTT is too sensitive [1]. ACT should 
achieve 300–350 s in NOAC- or VKA-treated patients [1]. 
Dabigatran can be restarted 3–4 h after sheath removal 
in patients with an adequate hemostasis and the absence 
of a pericardial effusion [1]. Maximal anticoagulation ef-
fect is achieved within 2 h of ingestion [1]. Despite a low 
bleeding risk, our patient had a major bleeding (hemoglo-
bin dropped to 7.2 g/dl) requiring transfusion of 3 PRBC 
units (proceedings in dabigatran-related bleedings are 
Table 1. Pharmacokinetic differences between dabigatran etexilate and acenocoumarol (based on the antithrombotic guidelines of the 
American College of Chest Physicians [ACCP] [9])
Parameter Dabigatran Acenocoumarol
Mechanism — site of actions in the coa-
gulation cascade
Direct inhibitor of factor II (thrombin) Reduced synthesis of coagulation factors 
vitamin K-dependent (II, VII, IX, X, protein C 
and protein S)
Half-live [h] 12–14 8–11
Bioavailability [%] ~6 > 60
Time to reach maximum serum concen-
trations [h]
0.5–2 36–48*
Dose 2 ×/day, fixed dosing** 1 ×/day, dosage maintenance established 
with INR monitoring
Clearance non-renal/renal of absorbed 
dose (normal renal function) [%]
20/80 30/60
Plasma protein binding [%] 35 99
Metabolism by cytochrome P450 No Yes (mainly CYP2C9)
Interactions with drugs and food Low potential for interactions Variety mechanisms of interaction 
Antidote Humanized monoclonal antibody frag-
ment (Fab) — idarucizumab
Fast reversal effect using PCC or FFP, slow 
reversal onset using vitamin K
*It takes 2–3 days to exert its full effect; **50 mg 2 ×/day (110 mg 2 ×/day dose in renal impairment); PCC — prothrombin complex concentrate; FFP — fresh frozen plasma
Table 2. Patients undergoing a planned surgical intervention or ablation: when to stop dabigatran therapy? (based on European Heart 
Rhythm Association [EHRA] Practical Guide [1])
Creatinine clearance 
[mL/min]
Bleeding risk
Low risk [h] High risk [h]
≥ 80 ≥ 24 ≥ 48
50–80 ≥ 36 ≥ 72
30–50 ≥ 48 ≥ 96
< 30 Not indicated Not indicated
When there is no major bleeding risk and normal creatinine clearance performed ≥ 12 or 24 h after last intake of dabigatran
There is no need for bridging with LMWH/UFH when dabigatran is used
Bleeding risk factors: patient’s age (≥ 75 years), renal and liver dysfunction, weight (≤ 60 kg), drug interactions (antiplatelets; NSAIDs; 
systemic steroid therapy; other anticoagulants), history of GI bleeding, thrombocytopenia (e.g. chemotherapy), HAS-BLED ≥ 3, recent 
surgery on critical organ (brain, eye)
LMWH — low molecular weight heparin; UFH — unfractionated heparin; NSAIDs – nonsteroidal anti-inflammatory drugs; GI — gastrointestinal
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shown in Figure 4). From recent idarucizumab approval, 
there is a possibility of rapid reverse of the dabigatran 
anticoagulant action, in case of a need for an emergent 
surgery or a life-threatening bleeding [1]. However, at that 
time idarucizumab was still unavailable in our hospital and 
probably it would not change the prognosis of the patient. 
Dabigatran was continued since next day after ablation 
when hemoglobin concentration stabilized.
A pocket hematoma is an acute complication after 
a device implantation [6]. It occurs in 2–4% of cases, but 
the risk is increased in anticoagulated patients (up to 
12–23%) [6]. The 2nd case presented a patient with a pocket 
hematoma developed over few days after ICD implantation. 
This patient required an adequate anticoagulation because 
of a valvular-AF and a post-thrombotic syndrome. However, 
he had also an increased risk of a VKA-related bleeding 
due to advanced age, severe heart and renal failure. His 
INR level was appropriate (2.21) but he had prolonged 
APTT (52.9 s). In consequence, the bleeding exacerbated 
anemia and acenocoumarol was suspended (proceedings 
in planned procedures and bleedings on acenocoumarol 
treatment are shown in Table 3 and Figure 5, respectively). 
Because of a considerable size of hematoma, our patient 
required a surgical intervention. Based on the literature, 
surgical hematoma evacuation is required in 1–2% [6]. 
Pocket hematoma related to device implantation is also 
associated with an increased risk of infection and often 
leads to prolonged hospital stays [6].
The 3rd case presented a FAP in the right groin of 
a patient who underwent transcutaneous radiofrequency 
ablation. A FAP is one of the most undesirable complica-
tions after invasive procedures and its incidence is still 
increasing [7]. A FAP is associated with anticoagulation 
and there is a need for further research on the use of 
Figure 4. Possible management of bleeding complications on dabigatran therapy (based on European Heart Rhythm Association [EHRA] 
[1]); RBC — red blood cells; FFP — fresh frozen plasma; i.v. — intravenous; aPCC — activated prothrombin complex concentrate; rFVIIa — 
recombinant factor VIIa
Bleeding complications on dabigatran therapy
•Investigate the source of bleeding
•Blood sample to determine creatinine clearance, hemoglobin and RBC
•Inquire about last dosage of anticoagulant
Mild bleeding Moderate severe bleeding Life-threatening bleeding
Delay next dose 
or discontinue
Consider additionally:
•surgical or endoscopic hemo-
   stasis (hemodialysis if needed)
•fluid replacement
•RBC substitution
•FFP (as plasma expander)
•platelet substitution
•idarucizumab 5 g i.v.
Consider additionally:
•idarucizumab 5 g i.v.
•PCC 50 U/kg; +25 U/kg
•aPCC 50 U/kg; 
   max 200 U/kg/day
•rFVIIIa 90 μg/kg
Table 3. Patients undergoing a planned surgical intervention or ablation: when to stop vitamin-K antagonists (VKA) therapy? (based on 
the antithrombotic guidelines of the American College of Chest Physicians [ACCP] [10])
The risk for thrombo-embolism Vitamin-K antagonists
Low Discontinue drug for up to 48 h (to obtain normal INR)
If despite the discontinuation of VKA INR is still ≥ 1.5
1–2 days before surgery → administrate p.o. 1–2 mg of vitamin K1
High Additionally, need for bridging with LMWH/UFH
Bleeding risk factors: INR > 5 (significant increase in risk), patient’s age (> 65 years), history of GI bleeding, concomitant diseases 
(cancer, renal and liver disease, uncompensated hypertension, ischemic stroke, alcoholism), drug interactions (antiplatelets, NSAIDs), 
thrombocytopenia
INR — international normalized ratio; LMWH — low molecular weight heparin; UFH — unfractionated heparin; GI — gastrointestinal; NSAIDs — nonsteroidal anti-inflammatory drugs
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dabigatran in patients with a FAP [7]. In our patient a FAP 
appeared on the next day after ablation. The probability 
of a spontaneous FAP closure remarkably decreases in 
patients on anticoagulation and it usually needs a thrombin 
injection [7]. Conservative treatment can be used in not 
anticoagulated patients with small (< 2 cm) and asymp-
tomatic pseudo-aneurysms [7]. FAP due to a severe pain 
and large dimensions (> 3 cm, which is a significant risk of 
a pseudoaneurysm rupture [7]) required an intervention. In 
patients with normal creatinine clearance and with a low 
risk of bleeding, interventions can be performed 12–24 h 
after the last dabigatran intake (Table 2) [1]. However, our 
case confirms a possibility of a successful pseudoaneurysm 
closure without dabigatran suspension, which is consistent 
with Dzijan-Horn et al. recommendations [8].
Conclusions
Periprocedural oral anticoagulation depends on the anti-
coagulant type and requires individual assessment of the 
patient’s thromboembolic and bleeding risk factors. Our 
study shows that in case of a bleeding, dabigatran may be 
quickly stopped and then restarted recently after reaching 
hemostasis, in contrast to acenocoumarol. It also confirms 
a possibility of a successful pseudoaneurysm closure wit-
hout dabigatran suspension.
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Figure 5. Possible management of bleeding complications on 
acenocoumarol therapy (based on the antithrombotic guidelines of 
the ACCP [10]); INR — international normalized ratio; p.o. — per os; 
i.v. — intravenous; aPCC — activated prothrombin complex concen-
trate; FFP — fresh frozen plasma; rFVIIa — recombinant factor VIIa; 
RBC — red blood cells
Bleeding complications on vitamin K antagonists therapy
Mild bleeding Moderate to severe bleeding 
•Check INR
•If INR > 4.5 < 10, omit 
   dose and restart when 
   INR in therapeutic range
•If INR > 10, manage 
   as above and give 
   vitamin K 2.5–0.5 mg p.o.
   Dose may be repeated
• Contact consultant 
   hematologist
•Give vitamin K 5–10 mg i.v. 
   Consider dose repeating
•Consider aPCC more 
   than FFP
•Consider rFVIIIa 90 μg/kg
•Consider RBC substitution
Streszczenie
Zastosowanie dabigatranu, doustnego antykoagulantu niebędącego antagonistą witaminy K, jest coraz powszechniej-
sze. Z jednej strony dabigatran cechuje się dobrą skutecznością i bezpieczeństwem, a także bardziej przewidywalnym 
działaniem przeciwzakrzepowym niż antagoniści witaminy K. Z drugiej strony jest acenokumarol/warfaryna, antagonista 
witaminy K, który oceniano w wielu badaniach klinicznych — lek z wyboru w zastawkowym migotaniu przedsionków.
Na podstawie przypadków klinicznych autorzy starali się podsumować aktualne zalecenia postępowania w przypadku 
okołozabiegowych powikłań podczas doustnego leczenia przeciwkrzepliwego. W 1. przypadku zaprezentowali pacjenta 
stosującego dabigatran, poddanego izolacji żył płucnych, u którego po zabiegu wystąpił krwiak prawej pachwiny i w kon-
sekwencji chory wymagał kilku transfuzji krwi. W 2. przypadku opisali pacjenta stosującego acenokumarol, z wysokim 
ryzykiem krwawienia, u którego pojawił się krwiak loży pooperacyjnej po implantacji kardiowertera-defibrylatora. Przed-
stawiono również pacjenta poddanego terapii dabigatranem, u którego wystąpił tętniak rzekomy prawej tętnicy udowej 
po zabiegu izolacji żył płucnych.
Okołozabiegowa doustna antykoagulacja zależy od rodzaju antykoagulantu oraz wymaga indywidualnej weryfikacji czynników 
ryzyka krwawienia i prozakrzepowych u danego pacjenta. Opisy tych przypadków pokazały, że jeśli wystąpi krwawienie, to 
dabigatran można szybko odstawić i ponownie włączyć niedługo po osiągnięciu hemostazy, w przeciwieństwie do acenoku-
marolu. Potwierdzają one również możliwość pomyślnego zamknięcia tętniaka rzekomego bez odstawiania dabigatranu.
Słowa kluczowe: acenokumarol, dabigatran, krwiak, komplikacje okołozabiegowe, izolacja żył płucnych, wszczepialny 
kardiowerter-defibrylator, tętniak rzekomy
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